Loading

Please wait...

Samsca

Generic Name: tolvaptan (tol VAP tan)
Brand Names: Samsca
Samsca (tolvaptan) is used to treat hyponatremia (low levels of sodium in your blood) in patients with heart failure and liver disease. Includes Samsca side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Samsca

Set your location
for drug prices near you

Enter your zip code

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Samsca (tolvaptan) reduces the level of a hormone that regulates the balance of water and salt (sodium) in the body. High levels of this hormone can cause an imbalance that results in low sodium levels and fluid retention. Samsca is used to treat hyponatremia (low levels of sodium in your blood) in people with heart failure, and certain hormonal imbalances. Samsca improves urine flow without causing the body to lose too much sodium as you urinate. This medication guide prOvides information about the Samsca brand of tolvaptan. Jynarque is another brand of tolvaptan that is not covered in this medication guide. Learn more

Samsca Side Effects

Samsca Side Effects

Note: This document contains side effect information about tolvaptan. Some of the dosage forms listed on this page may not apply to the brand name Samsca.

In Summary

Common side effects of Samsca include: polyuria, increased thirst, pollakiuria, and xerostomia. Other side effects include: constipation, fever, hyperglycemia, increased serum alanine aminotransferase, and anorexia. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to tolvaptan: oral tablet

Warning

Oral route (Tablet)

Samsca® should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too-rapid correction of hyponatremia (eg, greater than 12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and death. Slower rates of correction may be advisable in susceptible patients (eg, those with severe malnutrition, alcoholism, or advanced liver disease).Samsca® Not For Use For Autosomal Dominant Polycystic Kidney Disease (ADPKD): Because of the risk of hepatoxicity, tolvaptan should not be used for ADPKD outside of the FDA-approved REMS.

Oral route (Tablet)

Warning: Risk Of Serious Liver Injury:Jynarque(TM) (tolvaptan) can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported.Measure ALT, AST and bilirubin before initiating treatment, at 2 weeks and 4 weeks after initiation, then monthly for the first 18 months and every 3 months thereafter. Prompt action in response to laboratory abnormalities, signs, or symptoms indicative of hepatic injury can mitigate, but not eliminate, the risk of serious hepatotoxicity.Because of the risks of serious liver injury, Jynarque(TM) is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS) called the Jynarque(TM) REMS Program.

Along with its needed effects, tolvaptan (the active ingredient contained in Samsca) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tolvaptan:

More common

  • Blurred vision
  • dry mouth
  • flushed, dry skin
  • frequent urination
  • fruit-like breath odor
  • increased hunger
  • increased thirst
  • increased urination
  • increased volume of pale, dilute urine
  • nausea
  • stomach pain
  • sweating
  • thirst
  • troubled breathing
  • unexplained weight loss
  • unusual tiredness or weakness
  • vomiting

Less common

  • Anxiety
  • blood in the urine
  • bloody stools
  • blue lips, fingernails, or skin
  • bruising
  • chest pain
  • confusion
  • cough
  • coughing or vomiting blood
  • dark urine
  • dizziness or lightheadedness
  • fainting
  • fast, slow, irregular, or shallow heartbeat
  • fever
  • irregular, fast or slow, or shallow breathing
  • loss of consciousness
  • muscle cramp, spasm, pain, or stiffness
  • pain, redness, or swelling in the arm or leg
  • persistent bleeding or oozing from puncture sites, mouth, or nose
  • pink or red urine
  • rash
  • rectal bleeding
  • stomach tenderness
  • troubled breathing
  • sweating
  • vaginal bleeding

Incidence not known

  • Difficulty swallowing
  • general feeling of tiredness or weakness
  • headache
  • high blood pressure
  • hives, itching, skin rash
  • irritability
  • light-colored stools
  • muscle twitching
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • restlessness
  • seizures
  • stomach pain, continuing
  • swelling of the feet or lower legs
  • tightness in the chest
  • yellow eyes or skin

Some side effects of tolvaptan may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Difficulty having a bowel movement
  • lack or loss of strength

Less common

  • Loss of appetite
  • weight loss

For Healthcare Professionals

Applies to tolvaptan: oral kit, oral tablet

Cardiovascular

Common (1% to 10%): Intracardiac thrombus, ventricular fibrillation, orthostatic hypotension

Gastrointestinal

Very common (10% or more): Dry mouth (up to 13%), nausea

Common (1% to 10%): Constipation, ischemic colitis, gastrointestinal bleeding, diarrhea

General

The most frequently reported side effects included thirst, dry mouth (up to 13%), asthenia, constipation, pollakiuria or polyuria and hyperglycemia.

Genitourinary

Common (1% to 10%): Blood in urine

Uncommon (0.1% to 1%): Urethral hemorrhage, vaginal hemorrhage

Hematologic

Common (1% to 10%): Prolonged prothrombin time, disseminated intravascular coagulation

Musculoskeletal

Common (1% to 10%): Rhabdomyolysis

Nervous system

Common (1% to 10%): Cerebrovascular accident, syncope, dizziness, headache

Uncommon (0.1% to 1%): Dysgeusia

Postmarketing reports: Osmotic demyelination syndrome

Renal

Very common (10% or more): Pollakiuria and polyuria (11%)

Uncommon (0.1% to 1%): Renal impairment

Respiratory

Common (1% to 10%): Pulmonary embolism, respiratory failure

Metabolic

Common (1% to 10%): Hyperglycemia, anorexia, diabetic ketoacidosis, dehydration, hyperkalemia, decreased appetite, creatinine increased, hypernatremia, hypoglycemia, hyperuricemia

Dermatologic

Common (1% to 10%): Ecchymosis, pruritus

Uncommon (0.1% to 1%): Pruritic rash

Hepatic

Common: Alanine aminotransferase increased, aspartate aminotransferase increased, bilirubin increased

Hypersensitivity

Postmarketing reports: Hypersensitivity reactions including anaphylactic shock and generalized rash

Other

Very common (10% or more): Thirst (up to 18%)

Common (1% to 10%): Asthenia, pyrexia, malaise

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Samsca (www.drugs.com/samsca.html).